Skandinaviska Enskilda Banken (SEB)
SAGE

Skandinaviska Enskilda Banken (SEB)’s Sage Therapeutics SAGE Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$456K – 871
2025
Q2 		$456K Buy
+50,000
New +$368K ﹤0.01% 712
2021
Q4 		– Sell
-12,608
Closed -$559K – 1057
2021
Q3 		$559K Sell
12,608
-67,100
-84% -$3.08M ﹤0.01% 858
2021
Q2 		$4.53M Buy
79,708
+18,700
+31% +$1.32M 0.03% 441
2021
Q1 		$4.57M Buy
61,008
+58,908
+2,805% +$4.83M 0.03% 416
2020
Q4 		$182K Buy
+2,100
New +$155K ﹤0.01% 1009
2020
Q3 		– Sell
-6,600
Closed -$274K – 1106
2020
Q2 		$274K Buy
+6,600
New +$240K ﹤0.01% 882

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s SAGE Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 50,000 shares — an estimated $456K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in SAGE in Q2 2020 and held it in 6 quarters. The position peaked at $4.57M in Q1 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 50,000 Sage Therapeutics shares in Q3 2025, an estimated $456K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Sage Therapeutics in Q2 2020 and held it in 6 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Sage Therapeutics position peaked at $4.57M in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.